Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- breast cancer: an umbrella review.
Journal Information
Full Title: J Cancer Res Clin Oncol
Abbreviation: J Cancer Res Clin Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Conflict of interestThe authors declare that they have no conflict of interest. Ethical approvalThis article does not contain any studies conducted by the authors on human participants or animals. Conflict of interest The authors declare that they have no conflict of interest."
"Funding This study was supported by National Natural Science Foundation of China (82374452), the Academic Leaders of the 2022 High-Level Talent Training Program in Chinese Medicine (2022-73), and the Emerging Tumor Supportive Therapy Topic (cphcf-2022-191)."
"An umbrella review of the clinical efficacy of CDK4/6 inhibitors for the treatment of breast cancer patients was performed according to the Preferred Reporting Items for Systematic Evaluation and Meta-Analysis (PRISMA) program. The protocol has been previously published and registered in The International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42022350167)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025